Specialty Products Top 25% Of Total Rx Spend And Growth To Accelerate – Express Scripts
This article was originally published in The Pink Sheet Daily
Express Scripts’ annual Drug Trend Report shows cause for continued payer concern about spending on specialty drugs, with those products accounting for nearly 28% of total commercial drug spend in 2013 and projected spending growth of 64% over the next three years.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.